Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Dundee
Headquarters: Dundee, Scotland, United Kingdom
Website: http://www.dundee.ac.uk
Year Founded: 1881
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Oct 3, 2024
Discovery & Translation
Type 2 cytokines for durable cancer remission, drugging GTPases: BioCentury’s Science Spotlight
BioCentury’s roundup of translational innovations
BioCentury | May 23, 2024
Product Development
Amphista degrades a cancer target using a non-traditional ligase
Amphista’s targeted glues combine the advantages of PROTACs and molecular glues to create selective, orally bioavailable therapies
BioCentury | May 6, 2024
Product Development
Tale of two WRN inhibitors: a covalent and a non-covalent molecule enter the clinic
As the first two programs targeting the helicase WRN enter the clinic for MSI+ cancers, they set up a comparison of different inhibitory mechanisms
BioCentury | Feb 24, 2024
Discovery & Translation
Science spotlight: New class of molecular glues, gene therapy for FTD/ALS and more
BioCentury’s roundup of translational innovations
BioCentury | Dec 7, 2022
Distillery Therapeutics
A SMARCA2-degrading PROTAC for SMARCA4-deficient cancer
BioCentury | Oct 14, 2022
Discovery & Translation
Codiak’s pan beta-coronavirus vaccine; plus CNS-penetrating AAV9 variants and more
BioCentury’s roundup of translational news
BioCentury | May 6, 2022
Deals
More pharma buy-in for Amphista’s non-E3 ligase degraders
Deals with BMS and Merck KGaA, and investment from Novartis and Lilly, highlight interest in broadly expressed, essential degradation machinery
BioCentury | Oct 23, 2021
Discovery & Translation
ESGCT preclinical roundup; plus Generation, Pionyr and more
BioCentury’s roundup of translational news
BioCentury | Aug 13, 2021
Product Development
Aug. 12 Quick Takes: another hold for Aprea’s eprenetapopt
Plus Vyne, AlzeCure and Jazz
BioCentury | Aug 22, 2020
Emerging Company Profile
Amphista: broadening the target space of protein degradation
Amphista raised $7.5M to test its targeted protein degradation platform
Items per page:
1 - 10 of 88